Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study
British Journal of Clinical Pharmacology · 2024-12 · 90 (12) · 3242-3251
DOI: 10.1111/bcp.16202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 18.08.2024. Verfasst von Lan Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Warren, New Jersey, USA. Hauptthemen laut MEDLINE: Huntingtin Protein, Huntington Disease. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PTC Therapeutics.
Abstract (Originalsprache)
Aims
PTC518 is an orally administered, centrally and peripherally distributed huntingtin ( HTT ) pre‐mRNA splicing modifier being developed for the treatment of Huntington's disease (HD) for which there is a high unmet medical need as there are currently no approved disease‐modifying treatments. This first‐in‐human study investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PTC518 in healthy volunteers.
Methods
This phase 1, single‐centre, randomized study in 77 healthy male and female volunteers evaluated the safety and tolerability and PK of PTC518 following single ascending doses and multiple ascending doses, PD as assessed by HTT mRNA and HTT protein levels after single and multiple doses, and food effects.
Results
PTC518 demonstrated a favourable safety profile. The majority of treatment‐emergent adverse events were mild and transient. PTC518 T max was reached at 6–7 h and the terminal T 1/2 was 54.0–75.3 h following a single oral dose. Exposure increased with dose though less than dose proportionally. The PTC518 concentrations in cerebrospinal fluid were approximately 2.6‐fold higher than the unbound free‐drug concentrations in plasma. A significant dose‐dependent reduction of up to approximately 60% in HTT mRNA and a significant dose‐dependent, time‐dependent and sustained reduction in HTT protein levels of up to 35% were observed after PTC518 treatment.
Conclusions
PTC518 was well tolerated, and proof of mechanism of this novel splicing modifier was demonstrated by the dose‐dependent decrease in systemic HTT mRNA and HTT protein levels. Results from this first‐in‐human study support further studies in patients with HD and demonstrate the potential for PTC518 as a breakthrough treatment for HD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PTC Therapeutics, Warren, New Jersey, USA.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
ORCID-Profile: Lan Gao, Khalid Abd-Elaziz
Förderung
- PTC Therapeutics
Zitieren
APA
Gao, L., Bhattacharyya, A., Beers, B., Kaushik, D., Bredlau, A. L., Kristensen, A., Abd-Elaziz, K., Grant, R., Golden, L., & Kong, R. (2024). Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study. British Journal of Clinical Pharmacology, 90(12), 3242-3251. https://doi.org/10.1111/bcp.16202
Vancouver
Gao L, Bhattacharyya A, Beers B, Kaushik D, Bredlau AL, Kristensen A, et al. Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study. British Journal of Clinical Pharmacology. 2024;90(12):3242-3251. doi:10.1111/bcp.16202
BibTeX
@article{Gao2024,
author = {Gao, Lan and Bhattacharyya, Anuradha and Beers, Brian and Kaushik, Diksha and Bredlau, Amy-Lee and Kristensen, Allan and Abd-Elaziz, Khalid and Grant, Richard and Golden, Lee and Kong, Ronald},
title = {Pharmacokinetics and pharmacodynamics of PTC518, an oral huntingtin lowering splicing modifier: A first‐in‐human study},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
volume = {90},
number = {12},
pages = {3242--3251},
doi = {10.1111/bcp.16202}
}
EUVIMED